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Abstract
Background—HIV-1 group M viruses diverge 25%–35% in envelope, important for viral
attachment during infection, and 10–15% in the pol region, under selection pressure from common
antiretrovirals. In Asia, subtypes B and CRF01_AE are common genotypes. Our objectives were
to determine whether clinical, immunologic or virologic treatment responses differed by genotype
in treatment-naïve patients initiating first-line therapy.
Methods—Prospectively collected, longitudinal data from patients in Thailand, Hong Kong,
Malaysia, Japan, Taiwan and South Korea were provided for analysis. Covariates included
demographics, hepatitis B and C coinfections, baseline CD4 T lymphocyte count and plasma
HIV-1 RNA levels. Clinical deterioration (a new diagnosis of CDC category B/AIDS-defining
illness or death) was assessed by proportional hazards models. Surrogate endpoints were 12-month
change in CD4 cell count and virologic suppression post-therapy, evaluated by linear and logistic
regression, respectively.
Results—Of 1105 patients, 1036 (93.8%) infected with CRF01_AE or subtype B were eligible
for inclusion in clinical deterioration analyses and contributed 1546.7 person-years of follow-up
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(median:413 days, IQR:169–672 days). Patients >40 years demonstrated smaller immunological
increases (p=0.002) and higher risk of clinical deterioration (HR=2.17; p=0.008). Patients with
baseline CD4 cell counts >200 cells/μL had lower risk of clinical deterioration (HR=0.373;
p=0.003). A total of 532 patients (48.1% of eligible) had CD4 counts available at baseline and 12
months post-therapy for inclusion in immunolgic analyses. Patients infected with subtype B had
larger increases in CD4 counts at 12 months (p=0.024). A total of 530 patients (48.0% of eligible)
were included in virologic analyses with no differences in response found between genotypes.
Conclusions—Results suggest that patients infected with CRF01_AE have reduced
immunologic response to therapy at 12 months, compared to subtype-B-infected counterparts.
Clinical deterioration was associated with low baseline CD4 counts and older age. The lack of
differences in virologic outcomes suggests that all patients have opportunities for virologic
suppression.
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Introduction
HIV-1 group M viruses account for most infections internationally 1 and, based on genetic
similarity, are classified into nine different subtypes (A–D, F–H, J, K). Variants, however,
diverge 25%–35% in envelope (env), important for viral attachment to target cells during
infection, and 10–15% in the pol region, under selection pressure from common
antiretrovirals (ARVs) 1–3. Subtypes A and F are further divided into sub-subtypes A1, A2
and F1, F2, respectively. Although subtypes B and D are as similar as sub-subtypes, for
historical reasons they maintain separate subtype classification 1. Formerly, HIV-1 genotype
assignments were based on gene fragments. Later, when gag and pol regions were
genotyped, subtype E env viruses were found to include subtype A sections in the other
regions of the viral genome, resulting in subtype E’s reclassification as an A/E recombinant,
CRF01_AE 4. Circulating recombinant forms (CRFs) result from recombination between
HIV-1 genotypes within a dually infected person 1 but no complete subtype E genome has
been found, leaving CRF01_AE’s recombinant status inconclusive.
Subtype B is the genotype historically common in developed countries and nucleotide
substitutions (mutations or naturally occurring polymorphisms), insertions and deletions in
the HIV-1 genome are made in reference to the earliest characterised subtype B wild-type
strain, HXB2 5,6. ARVs, commonly designed on subtype B, are classified based on where
the HIV-1 life cycle is interrupted. Synergistic combinations of ARVs, known as highly
active antiretroviral therapy (HAART), suppress viral load (VL) thereby reducing the risk of
opportunistic infections and death 7,8. However, natural drug-resistant polymorphisms may
exist in patients pre-therapy with higher frequencies being found in non-B subtypes 9.
In vitro studies suggest differences in viral transmission characteristics between genotypes
and viral heterogeneity may have implications for disease progression. HIV-1 infection
depends on the interaction of env gp120 with the target cell CD4 receptor 10 and this
interaction promotes binding to a coreceptor, viral tropism being determined by the env
amino acid sequence and structure. Most genotypes use R5 coreceptors during transmission
and in early stages of infection with X4-using syncytium inducing variants emerging
later 11,12. Subtype C studies generally report a lack of coreceptor switching from R5 to X4,
possibly affecting transmission 11, and dual tropic virus (X4/R5) found in other genotypes
have not been reported in subtype D viruses 13. Where subtypes A and D co-circulate, more
rapid disease progression has been found for subtype D compared with subtype A 14
although the literature suggests that subtype A infections are outpacing subtype D 15. A
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retrospective analysis found faster rates of CD4 decline and virologic failure in subtype D
infection compared to subtypes A, B or C suggesting differences in HIV-1 genotypes with
respect to patient response to therapy 16.
In Asia, predominant genotypes are subtypes B and C, CRF01_AE and their recombinants,
with country-specific epidemics featuring different group M genotypes. During 2000–2007,
in India, approximately 97% of infections were from subtype C while four Mekong River
countries (Cambodia, Myanmar, Thailand and Viet Nam) reported almost 80% of infections
were from CRF01_AE 17. Subtype B infections are primarily reported in Japan and the
Republic of Korea (South Korea) 17–20. In China’s Special Administrative Region of Hong
Kong and in Malaysia, subtype B and CRF01_AE co-circulate 17,21,22 while in Taiwan,
subtype B, CRF01_AE and CRF07_BC have been found 23,24. Epidemic distributions differ
depending on the sub-populations at risk with subtype B frequently found in injecting drug
users and men-who-have-sex-with-men (MSM), whereas CRF01_AE is more commonly
found in heterosexual populations 25.
Previously we reported that mainly CRF01_AE and subtype B were infecting patients from
Thailand, Hong Kong and Malaysia 26. The objectives were to determine whether treatment
responses (clinical deterioration, immunologic response or virologic suppression) differed
between these genotypes in treatment-naïve patients initiating a first-line HAART regimen.
Methods
Patient data
Patients providing data were enrolled in either the TREAT Asia Studies to Evaluate
Resistance monitoring protocol (TASER-M) 26 or the TREAT Asia HIV Observational
Database (TAHOD) 27. Data for these longitudinal, cohort studies are collected
prospectively. Most TASER-M sites are selected from TAHOD sites which consist of
government- or university-based clinics and hospitals or private clinics, situated in major
cities and other urban areas. Pre-treatment drug resistance prevalence for the TASER-M
cohort has been published elsewhere 28. Clinical interventions and testing procedures were
implemented according to local practices, excepting HIV-1 genotyping in TASER-M which
was collected under the protocol.
Treatment-naive patients were eligible for inclusion if they were initiating first-line HAART
regimens and had HIV-1 genotype available. Eligible patients enrolled at March 2010 from
11 clinic locations in Thailand (4), Hong Kong (China) (2), Malaysia (2), Japan (1), Taiwan
(1) and South Korea (1) provided prospective and retrospective data (TAHOD) for analysis.
Patient covariates included demographics (age at entry to cohort, gender, HIV source
exposure), hepatitis B (HBV) and hepatitis C (HCV) coinfections and baseline indices of
illness severity (CD4 lymphocyte count, HIV-1 RNA and CDC classification 29). The most
severe pre-therapy CDC category recorded was used as the baseline clinical status. HBV
(HCV) positive status was defined as having any HBsAg (HCV-Ab) positive result prior to
enrolment. HIV-1 genotypes were determined by Virco BVBA, Belgium. For assessing
associations between patient covariates and genotype, patients were restricted to those
infected with subtype B or CRF01_AE whose sequences passed Virco’s quality control
procedures. Due to small numbers, patients reporting injecting drug use exposure, receipt of
blood products, perinatal transmission or unknown exposure were collapsed into an “Other”
transmission category.
Analysis endpoints
Patients were required to have at least one clinic visit or test procedure recorded post-
therapy initiation for inclusion. Clinical deterioration was determined as a new diagnosis of
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a CDC B or C (AIDS-defining) illness or death from any cause. Patient follow-up
commenced at HAART initiation and ended at earliest clinical deterioration endpoint or
censored at the most recent contact. Surrogate endpoints were plasma HIV-1 RNA viral
suppression (< 400 copies/mL) and change in CD4 cell count from baseline at 12 months
post-HAART. For calculating the 12-month immunologic change, the surrogate marker
value closest to the 12-month target date was chosen from windows of 9–15 months and the
CD4 count sampled within the 91 days prior, and closest to therapy initiation, was selected
as the baseline value.
Statistical analysis
For eligible patients, baseline comparisons by country (χ2, Fisher’s exact or Cochrane-
Armitage test for trend) were performed, as appropriate. Determinants of change in CD4 cell
count and 12-month HIV-1 RNA suppression were assessed via linear regression and
logistic regression, respectively. Proportional hazards models were used to evaluate
predictors of time to progression to a new clinical deterioration endpoint. Analyses were
based on an intention-to-continue treatment approach in that we did not take into account
regimen changes or interruptions post-therapy. Forward stepwise techniques were used to
determine the best fitting models. Binary covariate p-values and multi-categorical parameter
p-values (from tests for trend/heterogeneity) of <0.1, in univariate analyses, were considered
for inclusion in multivariate patient covariate models. Final models consisted of patient
covariates remaining significant at the 0.05 level. Then, because of our a priori interest in
the effect of HIV-1 genotype on outcomes, we assessed the effect of HIV-1 genotype,
adjusting for any significant patient covariates, and tested for interactions between genotype
and cohort. Analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC,
USA) and STATA version 10 (STATA Corp., College Station, TX, USA).
Results
A total of 1105 ARV-naïve patients had HIV-1 genotype information available [TASER-M:
n=922 (83.4%); Thailand: n=675 (73.2%); Hong Kong: n=160 (17.4%); Malaysia: n=87
(9.4%); TAHOD: n=183 (16.6%); Japan: n=65 (35.5%); Hong Kong: n=49 (26.8%);
Taiwan: n=43 (23.5%); South Korea: n=15 (8.2%)]. Differences in ethnicity reflected
population distributions within countries contributing data [TASER-M; Thai: n=675
(73.2%), Chinese: n=177 (19.2%), Malay: n=37 (4.0%), Indian: n=11 (1.2%), Caucasian:
n=5 (0.5%); TAHOD; Thai: n=14 (7.7%), Chinese: n=88 (48.1%), Japanese: n=65 (35.5%),
Korean: n=15 (8.2%), Caucasian: n=1 (0.5%)].
Years of enrolment differed as a function of cohort recruitment and 80% of TAHOD
patients were enrolled prior to opening of the TASER-M cohort. Patients initiated therapy
from 2003–2010 (TASER-M: 2007–2010; TAHOD: 2003–2010) and significant differences
between cohorts were noted for covariates as shown in Table 1. All Table 1 covariates were
evaluated for significance in endpoint analyses.
Most first-line regimens included lamivudine (3TC) as a nucleoside/nucleotide reverse
transcriptase inhibitor (NRTI) backbone component [n=1013 (91.7%)]. Regimens for the
cohorts differed in the second NRTI component [TASER-M; stavudine (d4T): n=479
(52.0%); zidovudine (AZT): n=221 (24.0%); abacavir (ABC): n=67 (7.3%); TAHOD; d4T:
n=37 (20.2%); AZT: n=84 (45.9%); ABC: n=26 (14.2%), p<0.001]. Most regimens were
based on non-nucleoside reverse transcriptase inhibitors (NNRTIs) with more TAHOD
patients being prescribed efavirenz (EFV) and TASER-M patients’ regimens including
higher proportions of nevirapine (NVP) [TASER; NVP: n=484 (58.9%), EFV: n=338
(41.1%); TAHOD; EFV: n=77 (82.8%), NVP: n=16 (17.2%); p<0.001]. Of protease
inhibitor (PI) regimens, most included ritonavir-boosted atazanavir (ATZ) or lopinavir
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(LPV), proportions of which marginally differed between cohorts [TASER-M; ATZ/r: n=28
(38.9%), LPV/r: n=44 (61.1%); TAHOD; ATZ/r: n=17 (22.7%), LPV/r: n=58 (77.3%);
p=0.048].
In East Asia, there is a higher odds of CRF01_AE infecting heterosexual populations and
subtype B is more frequently found in MSM. We found differences in genotype proportions
consistent with patient-reported HIV source exposures (Table 1) [TASER-M; CRF01_AE:
n=740 (86.8%), subtype B: n=113 (13.2%); TAHOD; CRF01_AE: n=38 (20.8%); subtype
B: n=145 (79.2)%; p<0.001]. In TASER-M, both HIV-1 pol protease (PR) and reverse
transcriptase (RT) genotypes are recorded and 59 (6.4%) of TASER-M patients were
infected with discordant PR and RT genotypes, reflecting possible dual infection and/or
recombination. Of discordant genotypes, 28 (47.5%) included subtype B components
(assessed as including subtype B, CRF08_BC, CRF08_BC or CRF15_01B) and 23 (39.0%)
were CRF01_AE recombinants (assessed including CRF01_AE or CRF15_01B). The
remaining discordant genomes [n=8 (13.6%)] included both B and AE components.
Discordant genotypes and subtypes CRF02_AG (n=1), CRF 07_BC (n=3), C (n=5), subtype
D (n=1) were excluded from further evaluation.
Progression to CDC B or CDC C (AIDS-defining) illness or death
A total of 1036 patients (93.8%) infected with CRF01_AE or subtype B were eligible for
inclusion in clinical deterioration analyses (Table 2) and contributed 1546.7 person-years of
retrospective and prospective follow-up (median: 413 days, IQR: 169–672 days). During
this time, there were a total of 104 events (22 CDC B diagnoses, 63 AIDS diagnoses and 19
deaths) giving an event rate of 6.7 per 100 person-years [95% CI: 5.5–8.1]. Clinical
deterioration endpoints were recorded between 2003 and 2010 (TASER: n=76, range: 2007–
2010; TAHOD: n=28, range: 2003–2009). Significant univariate associations were found
with age group, baseline CD4 count and HIV-1 RNA viral load. After adjustment for Table
1 covariates, patients older than 40 years had higher risk of clinical deterioration (HR=2.17;
p=0.008) while patients having baseline CD4 cell counts greater than 200 cells/μL had lower
risk of clinical deterioration (HR= 0.373; p<0.003). A total of 450 (43.4%) patients
contributing to the clinical deterioration analyses were also included in immunologic and
virologic analyses.
Change in CD4 cell count at 12 months following HAART
For immunologic analyses, 532 patients (48.1% of eligible) had CD4 counts available at
baseline and at 12 months, with a median increase of 187.2 cells/μL over the period (Table
3). To calculate the change in CD4 over the period, baseline CD4 was subtracted from the
12-month result. In unadjusted analyses, smaller increases in CD4 counts were associated
with age older than 40 years while larger improvements were associated with being infected
with subtype B. Excluding patients with unknown baseline VL, compared to patients with
less than 10,000 copies/mL, patients with higher VLs evidenced larger increases. These
associations were maintained after adjustment for other covariates (Age>40 years; p=0.002;
Subtype B; p=0.024, HIV-1 RNA >=10,000 copies/mL; p=0.024). There was no interaction
between HIV-1 genotype and cohort membership (Change in CD4: TASER-M; median: 168
cells/μL, IQR: 100 – 252 cells/μL, TAHOD: median: 166 cells/μL, IQR: 101 – 250 cells/μL;
Interaction; p<0.402). As shown in Table 3, 459 (86.3%) patients had greater than 10,000
copies/mL at study entry. Median CD4 count increases for these patients, in all age
categories, were higher for subtype B-infected patients (Age<30 years; Subtype B: median:
185 cells/μL, IQR: 138–289, CRF01_AE: median: 178.5 cells/μL, IQR: 120–276; Age 30–
40 years; Subtype B: median: 251 cells/μL, IQR: 165–299, CRF01_AE: median: 176 cells/
μL, IQR: 99–250; Age>40 years; Subtype B: median: 157.5 cells/μL, IQR: 101.5–217,
CRF01_AE: median: 152.5 cells/μL, IQR: 76–218). Most patients infected with CRF01_AE
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came from Thailand [Thailand: n=288 (75.0%), Hong Kong: n=68 (17.7%), Malaysia: n=27
(7.0%), Taiwan: n=1 (0.3%)] whereas the majority of subtype B patients came from high-
income economies [Hong Kong: n=74 (50.0%), Taiwan: n=32 (21.6%), Japan: n=13 (8.8%)
South Korea: n=11(7.4%) vs. Thailand: n=15 (10.1%), Malaysia: n=3 (2.0%)]. TAHOD
patients from Japan and South Korea were only infected with subtype B but excluding these
patients from analyses did not impact upon interpretations.
HIV RNA at 12 months following HAART
Due to the heterogeneity of virology assays and associated dynamic ranges across sites, we
defined the lower limit of detection (LLD) as 400 copies/mL. Analyses included 530
patients (48.0% of eligible) who had an HIV-1 RNA result available at 12 months and
92.6% of patients were virologically suppressed below the LLD (TASER: n=383 (94.3%),
TAHOD n=108 (87.1%). Multivariate analyses showed no associations between the patient
characteristics shown in Table 1 and the virologic outcome.
Discussion
Subtype B and CRF01_AE have been circulating in Asia for more than 10 years 30 and we
report on the first evaluation of treatment responses in these genotypes in ARV-naïve
patients. Patients initiated therapy from 2003–2010 and findings from adjusted analyses
demonstrated that patients infected with subtype B had increased immunological response to
therapy, compared to CRF01_AE. A retrospective, cross-sectional study of mainly treated
patients also found lower immunologic response in CRF01_AE patients compared to
subtype B 9. However, our finding in treatment-naive patients is uncomplicated by genomic
variation attributable to drug selection pressures. A study from Singapore found increased
CD4+ T-cell loss in predominantly Chinese males infected with CRF01_AE 31 and, as
mentioned previously, studies in other cohorts have reported differences in HIV-1
transmission and disease progression. Several in vitro studies have suggested structural
reasons for these differences.
Patients older than 40 years had reduced immunologic response at 12-months while baseline
HIV-1 RNA greater than 10,000 copies/mL at study entry was predictive of larger CD4
counts increases, compared patients with lower viral burdens. Older patients with low CD4
counts pre-therapy had increased risk of clinical deterioration, consistent with the
literature 32. Comparisons of virologic suppression in other genotypes have yielded mixed
results 16,33 but we found no differences in virologic suppression post-HAART and
approximately 90% of patients achieved virologic suppression at 12-months post-therapy.
Patients being followed under protocol at funded study sites or with HIV-1 genotype
recorded in observational data suggest that site clinicians have diagnostic technologies
available to guide patient treatment. Consequently, treatment outcomes for our patients may
be better than those experienced in general clinic populations. Adherence information was
not available and limited follow-up for TASER-M patients may have contributed to our
nonsignificant finding in relation to clinical deterioration. Country differences were not
specifically controlled for although cohort membership may serve as a surrogate for these
effects. Separate PR and RT genotypes are not reported in TAHOD and we noted 6.4% of
discordant genotypes among the TASER-M patients. Therefore, a small proportion of
TAHOD patients with discordant genotypes may have been misclassified.
ARVs are commonly designed on subtype B. If immunologic response in the year following
HAART affects patient prognosis, our findings of a reduced response for patients infected
with CRF01_AE may possibly translate to a higher burden on country health systems, for
these patients than for their subtype-B infected counterparts. Studies of longer duration in
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representative patient populations, including socio-economic information and in vitro
studies are required to investigate this hypothesis. Patients starting therapy with low CD4
counts have been infected for some time and are commencing therapy later than
recommended by international guidelines 34,35. Late therapy initiation for patients from
developing economies generally reflects resourcing issues. However, for patients from high-
income Asian economies, this may be due to ignorance of HIV-positive status. Increased
testing to alert of HIV infection, before CD4 counts decrease substantially, should be
encouraged, particularly in high-risk groups.
Our finding of no differences in virologic response to treatment suggests that with
appropriate diagnostic testing, all patients have opportunities to suppress circulating virus to
non-detectable levels, thereby potentially increasing disease-free-survival. In addition to
being a welcome outcome for individual patients, levels of onward transmission are reduced
in virologically suppressed individuals 36.
The HIV pandemic is of increasing complexity and where genotypes co-circulate,
individuals coinfected with multiple variants provide HIV-1 opportunities for
recombination, augmenting viral diversity 37. We found discordant PR and RT genotypes in
6.4% of our patients, reflecting possible dual infection and/or recombination. Strategies such
as serosorting, where same HIV-status partners are sought for unprotected sex, have been
reported in MSM, as have higher frequencies of multi-variant transmission 38. Serosorting is
not supported as a risk reduction strategy and increases opportunities for recombination 39,
further complicating vaccine initiatives which seek to target transmitted virus.
Assays which evaluate patient circulating viral sequence for the presence of drug resistant
mutations also determine the circulating viral genotype. Although phylogenetic
investigations cannot determine the direction of HIV evolution, and, consequently the
direction of transmission in humans 40, mechanisms to capture genotypes resulting from
HIVDR testing at country-level may contribute to monitoring and quantification of HIV-1
diversity and genotypic proliferation in at-risk population networks 41. Genotyping
sequencing is expensive but there have been recent improvements in dried blood spot
methodologies, a less expensive alternative for specimen collection 42. Increased availability
of lower cost genotyping may contribute to local surveillance efforts.
In summary, our finding of reduced immunologic response in CRF01_AE-infected patients,
compared to subtype B, suggests that genotypic diversity impacts upon patient response to
treatment. Evidence of dual infection and recombination in our patients may suggest a need
for regional epidemic surveillance. Tracking of local variants may help to identify increasing
incidence of HIV-1 genotypes in at-risk groups and contribute to monitoring HIV-1
diversity and proliferation in the region.
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Table 1
Patient characteristics at first-line therapy initiation by cohort
TAHOD TASER P
n (%) n (%)
Age at entry (years)
 <30 46 (25.1) 172 (18.7) 0.2741
 30–40 67 (36.6) 395 (42.8)
 >40 70 (38.3) 355 (38.5)
Gender
 Male 160 (87.4) 595 (64.5) <0.0001
 Female 23 (12.6) 327 (35.5)
Exposure
 Heterosexual 59 (32.2) 688 (74.6) <0.0001
 Same sex contact 113 (61.7) 176 (19.1)
 Other 11 (6.0) 58 (6.3)
CDC classification
 Category A 102 (55.7) 434 (47.1) 0.0574
 Category B 17 (9.3) 110 (11.9)
 Category C 64 (35.0) 378 (41.0)
Hepatitis B
 Negative 123 (67.2) 606 (65.7) 0.8893
 Positive 14 (7.7) 68 (7.4)
 Not tested 46 (25.1) 248 (26.9)
Hepatitis C
 Negative 142 (77.6) 548 (59.4) <0.0001
 Positive 4 (2.2) 55 (6.0)
 Not tested 37 (20.2) 319 (34.6)
First-line regimen
 NNRTI 93 (50.8) 838 (90.9) <0.0001
 PI 90 (49.2) 84 (9.1)
Baseline HIV-1 viral load (copies/mL) a
 < 10,000 9 (4.9) 59 (6.4) 0.6890
 >= 10,000 94 (51.4) 760 (82.4)
 Unknown 80 (43.7) 103 (11.2)
Baseline CD4 count (cells/μL) a
 <= 100 37 (20.2) 444 (48.2) <0.0001
 100–200 40 (21.9) 201 (21.8)
 >200 49 (26.8) 191 (20.7)
 Unknown 57 (31.1) 86 (9.3)
HIV-1 genotype b
 01_AE 38 (20.8) 740 (80.3) <0.0001
 02_AG 0 (0.0) 1 (0.1)
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TAHOD TASER P
n (%) n (%)
 07_BC 0 (0.0) 3 (0.3)
 B 145 (79.2) 113 (12.3)
 C 0 (0.0) 5 (0.5)
 D 0 (0.0) 1 (0.1)
 Discordant 0 (0.0) 59 (6.4)
Total 183 (16.6) 922 (83.4)
a
Test performed on non-missing values.
b
Test performed on subtype B and CRF01_AE.
Abbreviations: CDC, Centers for Disease Control and Prevention NNRTI, non-nucleoside reverse transcriptase, PI, protease inhibitor.
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